In conclusion, the ADC of LR004‐VC‐MMAE could be a potential therapeutic agent for ESCC and other EGFR‐expressing malignancies, with a combination of antitumor activity and a desirable PK and safety profile in the mice model. Here, EGFR is linked to esophageal squamous cell carcinoma.